Print this page    •   Back to Web version of article

Press Release
New 600-mg Tablet Strength for Prezista (Darunavir)

February 26, 2008

On February 25, 2008, FDA approved a new 600-mg tablet strength for Prezista (darunavir), manufactured by Tibotec, Inc., Yardley, PA. The new 600-mg tablet facilitates dosing by reducing pill burden.

The recommended oral dose of Prezista tablets is 600 mg (two 300-mg tablets or one 600-mg tablet) twice daily taken with ritonavir 100 mg twice daily and with food.

The 600-mg formulation will be available in bottles of 60 tablets.

The 300-mg tablet will continue to be available.

Darunavir is a protease inhibitor, which inhibits the formation of mature virus in HIV infected cells.

[Editor's note from TheBody.com: The 600-mg tablet is not expected to be available in the United States until mid-May 2008, according to a Tibotec official. The official also noted that the price of the new tablet will be the same as two of the 300-mg tablets.]




This article was provided by U.S. Food and Drug Administration. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/treat/art45235.html

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.